Jeff Barklow, MD
Nephrology · South Salt Lake, UTNPI 1538166640
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.8% of the total across 78 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 20.7% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for nephrology clinicians in UT, where the typical reported total is $1,171.
Across 78 payments — averaging $17.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$277
- ANI Pharmaceuticals, Inc.$146
- Novartis$108
- Lilly USA, LLC$96
- AstraZeneca$93
- GSK$77
- plus $539 from 15 others
What the payments were for
- Food & beverage$1,32199%
- Education$161%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 16 | $277 |
| ANI Pharmaceuticals, Inc. | 15 | $146 |
| Novartis | 7 | $108 |
| Lilly USA, LLC | 3 | $96 |
| AstraZeneca | 5 | $93 |
| GSK | 4 | $77 |
| Vifor Pharma, Inc. | 3 | $74 |
| Nxstage Medical, Inc. | 1 | $69 |
| Boehringer Ingelheim | 3 | $53 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $46 |
| Travere Therapeutics, Inc. | 7 | $45 |
| Fresenius USA Marketing, Inc. | 2 | $37 |
| Chiesi USA, Inc. | 1 | $36 |
| Otsuka America Pharmaceutical, Inc. | 2 | $33 |
| Novo Nordisk | 1 | $32 |
| Bayer | 1 | $23 |
| Ardelyx, Inc. | 1 | $22 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $21 |
| Alnylam Pharmaceuticals Inc. | 1 | $20 |
| Calliditas Therapeutics US Inc. | 1 | $15 |
| Cormedix Inc. | 1 | $14 |
How this compares
$1,336 in reported general payments places this provider in the 50th percentile of 74 nephrology providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 73 | $78,334 |
| JardianceEmpagliflozin | 56 | $68,752 |
| Everolimus | 13 | $9,750 |
| Mycophenolate Mofetil | 26 | $3,428 |
| Sirolimus | 16 | $3,298 |
| Tacrolimus | 28 | $2,376 |
| Candesartan Cilexetil | 19 | $1,712 |
| Losartan Potassium | 145 | $1,711 |
| Tamsulosin Hcl | 72 | $1,534 |
| Calcitriol | 70 | $1,489 |
| Potassium Chloride | 50 | $1,452 |
| Carvedilol | 93 | $1,279 |
| Lisinopril | 152 | $1,272 |
| Spironolactone | 107 | $1,125 |
| Torsemide | 41 | $1,091 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $93 | $78,33473 claims |
| Boehringer IngelheimJardiance | $53 | $68,75256 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $146 | $35122 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 74 nephrology providers in Utah.
Other nephrology in South Salt Lake
- Sanjiv AnandSouth Salt Lake$144K
- Sey LauSouth Salt Lake$3K
- Arasu GopinathSouth Salt Lake$3K
- Donald MorrisSouth Salt Lake$3K
- Ruth IndahyungSouth Salt Lake$3K
- Kevin JansenSouth Salt Lake$3K
- Roman ShingarevSouth Salt Lake$2K
- Indraneel MogaralaSouth Salt Lake$2K
- Dave TienSouth Salt Lake$2K
- Landon DicksonSouth Salt Lake$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.